Returning to tricyclic antidepressants for depression during childbearing: clinical and dosing challenges

被引:5
|
作者
Osborne, Lauren M. [1 ]
Birndorf, Catherine A. [2 ,3 ]
Szkodny, Lauren E. [4 ]
Wisner, Katherine L. [5 ,6 ]
机构
[1] Columbia Univ, Med Ctr, Dept Psychiat, Div Behav Med, New York, NY 10032 USA
[2] Cornell Univ, Weill Med Coll, Dept Psychiat, Payne Whitney Womens Program, New York, NY 10021 USA
[3] Cornell Univ, Weill Med Coll, Dept Obstet & Gynecol, Payne Whitney Womens Program, New York, NY 10021 USA
[4] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA
[5] Northwestern Univ, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA
[6] Northwestern Univ, Dept Obstet & Gynecol, Chicago, IL 60611 USA
关键词
Pregnancy; Depression; Anxiety; Nortriptyline; Pharmacokinetics; Tricyclic antidepressants; SEROTONIN-REUPTAKE INHIBITORS; PERSISTENT PULMONARY-HYPERTENSION; IN-UTERO EXPOSURE; NORTRIPTYLINE PHARMACOKINETICS; MAJOR DEPRESSION; BIRTH-DEFECTS; MATERNAL USE; PREGNANCY; RISK; POSTPARTUM;
D O I
10.1007/s00737-014-0421-z
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Managing depression and anxiety during pregnancy and the postpartum period is challenging. Both pharmacological treatment and the lack thereof can pose threats to a fetus. SSRIs are the drugs of choice for use during pregnancy, but there is considerable evidence for the safety and efficacy of older antidepressants during pregnancy as well. This study highlights a single case of the use of the tricyclic nortriptyline during pregnancy and postpartum. The subject involved had an unexpectedly high ratio of serum level to drug dose during the postpartum period. We monitored the subject for a significantly greater portion of the postpartum period than has been done in previous studies, and explored medical and lifestyle changes that could account for the level-to-dose ratios we observed. Differences in smoking patterns, coupled with the patient's status as a genetic poor metabolizer, were the most likely explanations.
引用
收藏
页码:239 / 246
页数:8
相关论文
共 50 条